CUA 2018: Current Management of M0 CRPC

Halifax, Nova Scotia (UroToday.com) Kim Chi, MD, gave an overview of the current treatment strategies for M0 castrate-resistant prostate cancer patients . The New England Journal of Medicine paper published by Juanita Crook in 2012 1 demonstrated that intermittent androgen deprivation therapy (ADT) was not inferior to continuous ADT for rising PSA after radiotherapy for prostate cancer (PC) patients (Figure 1). 

CUA 2018: Canadian Urology Workforce and Interprovincial Economics

Halifax, Nova Scotia (UroToday.com) In this talk, Omar Nazif, MD highlights the current states of the Canadian Urology workforce and subsequently addresses interprovincial economics. He was asked to give the talk as he has been working with CUA Health Policy committee on these issues. 

The first part was specifically an evaluation of the graduating residents between 2014-2016 to assess their challenges regarding finding employment. The basis for the evaluation was the following:

CUA 2018: Musings of a Former Deputy Health Minister

Halifax, Nova Scotia (UroToday.com) In this State of the Art Lecture, the invited speaker was Kevin McNamara, a former Deputy Health Minister from Nova Scotia. This talk was primarily his advice and recollection of the position and how to approach and work with ministers – as such, there was no substantive data presented nor were there any slides. Rather, this was very much just an oratory and retrospective. I will highlight a few points from his talk, though much of it was anecdotes.

CUA 2018: 1st and 2nd Line Therapy in Kidney Cancer: Practice Changing Trials

Halifax, Nova Scotia (UroToday.com) Sumanta Pal, MD, kicked off the CUOG meeting with a talk highlighting the major changes in renal cell carcinoma (RCC) systemic therapy management in the past year. 

The debates in advanced RCC management used to be limited to “Is high-dose IL-2 appropriate for everyone?” in the 1990’s, but in the past few years has been thrown into disarray with a dizzying number of new agents in this space. Ultimately, the goal is determining which agents allow our patients to live longer (ideally for a cure) and live better.

CUA 2018: Role of Cytoreductive Nephrectomy in 2018

Halifax, Nova Scotia (UroToday.com) This talk for kidney cancer focused on the role of cytoreductive nephrectomy in advanced/metastatic renal cell carcinoma (RCC). Ricardo Rendon, MD gave a talk summarizing the background work and recent publications. 

As systemic therapies continue to improve and change for advanced/metastatic RCC and are better tolerated, there has been increasing question of the role of cytoreductive nephrectomy (CNx) in this setting. Rendon was tasked to develop the CUA guidelines for this topic – unfortunately, after accumulating the data for this space, the recent CARMENA results were presented at ASCO 2018 and he was forced to adjust his report and slides significantly.